UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000035288 |
|---|---|
| Receipt number | R000039336 |
| Scientific Title | Clinical trial to establish optimal exercise therapy using near infrared spectroscopy(NIRS) to monitor Skeletal Muscle Oxygen Saturation(StO2) in patients with chronic limb ischemia |
| Date of disclosure of the study information | 2019/03/01 |
| Last modified on | 2022/03/17 17:44:34 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical trial to establish optimal exercise therapy using near infrared spectroscopy(NIRS) to monitor Skeletal Muscle Oxygen Saturation(StO2) in patients with chronic limb ischemia
Acronym
Clinical trial to establish optimal exercise therapy using near infrared spectroscopy(NIRS) to monitor Skeletal Muscle Oxygen Saturation(StO2) in patients with chronic limb ischemia
Scientific Title
Clinical trial to establish optimal exercise therapy using near infrared spectroscopy(NIRS) to monitor Skeletal Muscle Oxygen Saturation(StO2) in patients with chronic limb ischemia
Scientific Title:Acronym
Clinical trial to establish optimal exercise therapy using near infrared spectroscopy(NIRS) to monitor Skeletal Muscle Oxygen Saturation(StO2) in patients with chronic limb ischemia
Region
| Japan |
Condition
Condition
Chronic limb ischemia
Classification by specialty
| Cardiology | Rehabilitation medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Efficacy and safety of optimal exercise therapy in patients with Rutherford 4 or 5 chronic limb ischemia.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Amount of changes in maximum walking distance 6 months after revascularization treatment from registration.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Behavior,custom |
Interventions/Control_1
The optimal exercise therapy
Fixation exercise therapy is performed from the day after revascularization therapy, and optimal exercise therapy is started on 7th day after the treatment.
Optimal exercise therapy is based on the treadmill walking test and the evaluation of the hemodynamics by NIRS. The optimal exercise prescription is the walking speed of 80% of the walking speed at the end of treadmill walking test. Determination of optimal exercise therapy is at 7th day, 1st, 2nd, 3rd, 6th month after revascularization therapy. The amount of exercise is monitored and management using ACT watch during protocol period.
The optimal exercise therapy group should receive exercise instruction about once a week.
Interventions/Control_2
Traditional exercise therapy
The standard therapy (foot stretching, gymnastics, ankle exercise, etc.) that is required for critical limb ischemia is performed during hospitalization and instructed before discharge.
After that, visit the hospital for the same period as optimal exercise therapy group, and receive instruction about exercise therapy.
The amount of exercise is monitored and management using ACT watch during protocol period.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Male or female patients who aged 20 years or older and under 80 years of age at the time of signed informed consent form
2) Patients Who are scheduled to register for "regenerative therapy using mononuclear cells" or "regenerative therapy using autologous bone marrow mononuclear cells" under the act on the safety of regenerative medicine
3) Patients with Chronic limb ischemia whose Rutherford Classification is 4 or 5
4) Patient with measurable using NIRS at a designated site.
5) Patients who signed document consent of study participation obtained based on the patient's will and / or families' understanding and consent after receiving sufficient explanation about advantage/disadvantage arising from performing exercise therapy and advantage/disadvantage arising from not performing exercise therapy
Key exclusion criteria
1) Even if the disease or the surgical procedure is appropriate, informed consent can not be obtained from the patient, or patient's family need emotional consideration and it is difficult to adapt
2) Patients with life expectancy likely to be within one year due to complications
3) The untreated limb is Fontaine Classification III or more
4) Patient with active cancer treatment
5) Patient with ischemic heart disease who are not performed revascularization
6) Patients with untreated severe diabetic retinopathy
7) Patients with sever infection
8) Patients with significant liver impairment, significant renal impairment (except chronic maintenance dialysis)
9) Severe hematological disorder such as leucopenia and thrombocytopenia, and severe anemia requiring blood transfusions
10) Women who are pregnant or may be pregnant or lactating
11) Patients who have other severe acute / chronic medical / mental conditions or clinical laboratory test abnormalities, and there is a possibility that the risk may increase due to participation in the present study, or there is a possibility that it may affect interpretation of the result
12) Patients who can not be performed exercise therapy sufficiently due to cerebrovascular disease, bone nerve disease, lower limb amputation
13) Patients who the investigator or subinvestigator judged ineligible for the present study
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Satoaki Matoba |
Organization
Kyoto Prefectural University of Medicine
Division name
Department of Cardiovascular Medicine
Zip code
Address
465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto
TEL
075-251-5511
matoba@koto.kpu-m.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Kenji Yanishi |
Organization
Kyoto Prefectural University of Medicine
Division name
Department of Cardiovascular Medicine
Zip code
Address
465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto
TEL
075-251-5511
Homepage URL
yanishi@koto.kpu-m.ac.jp
Sponsor or person
Institute
Kyoto Prefectural University of Medicine
Institute
Department
Personal name
Funding Source
Organization
AMED
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 03 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2018 | Year | 12 | Month | 05 | Day |
Date of IRB
| 2019 | Year | 03 | Month | 12 | Day |
Anticipated trial start date
| 2019 | Year | 04 | Month | 01 | Day |
Last follow-up date
| 2023 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
| 2023 | Year | 09 | Month | 30 | Day |
Other
Other related information
Management information
Registered date
| 2018 | Year | 12 | Month | 17 | Day |
Last modified on
| 2022 | Year | 03 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039336
